A Potent and Selective PARP11 Inhibitor Suggests Coupling between Cellular Localization and Catalytic Activity

DOI: 10.1016/j.chembiol.2018.09.011
Cell Chemical Biology, 2018, 25, 1547-1553.e12.

#	Paper	IF	Citations
46	Small-Molecule Inhibitors of PARPs: From Tools for Investigating ADP-Ribosylation to Therapeutics. *Current Topics in Microbiology and Immunology*, **2019**, 420, 211-231	3.3	11
45	ADP-ribosyl-binding and hydrolase activities of the alphavirus nsP3 macrodomain are critical for initiation of virus replication. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E10457-E10466	11.5	58
44	Enabling drug discovery for the PARP protein family through the detection of mono-ADP-ribosylation. *Biochemical Pharmacology*, **2019**, 167, 97-106	6	23
43	A Focused DNA-Encoded Chemical Library for the Discovery of Inhibitors of NAD-Dependent Enzymes. *Journal of the American Chemical Society*, **2019**, 141, 5169-5181	16.4	51
42	Forced Self-Modification Assays as a Strategy to Screen MonoPARP Enzymes. *SLAS Discovery*, **2020**, 25, 241-252	3.4	12
41	In Vitro and Cellular Probes to Study PARP Enzyme Target Engagement. *Cell Chemical Biology*, **2020**, 27, 877-887.e14	8.2	9
40	Recent developments in PARP14 research. *Future Medicinal Chemistry*, **2020**, 12, 1657-1667	4.1	4
39	Mechanisms governing PARP expression, localization, and activity in cells. *Critical Reviews in Biochemistry and Molecular Biology*, **2020**, 55, 541-554	8.7	11
38	Interplay between compartmentalized NAD synthesis and consumption: a focus on the PARP family. *Genes and Development*, **2020**, 34, 254-262	12.6	32
37	PARPs and ADP-ribosylation: 60 years on. *Genes and Development*, **2020**,	12.6	10
36	Mono(ADP-ribosyl)ation Enzymes and NAD Metabolism: A Focus on Diseases and Therapeutic Perspectives. *Cells*, **2021**, 10,	7.9	5
35	Chemical genetics and proteome-wide site mapping reveal cysteine MARylation by PARP-7 on immune-relevant protein targets. *ELife*, **2021**, 10,	8.9	18
34	MARTs and MARylation in the Cytosol: Biological Functions, Mechanisms of Action, and Therapeutic Potential. *Cells*, **2021**, 10,	7.9	19
33	Recent development in the discovery of PARP inhibitors as anticancer agents: a patent update (2016-2020). *Expert Opinion on Therapeutic Patents*, **2021**, 31, 609-623	6.8	5
32	ADP-ribosylation of RNA and DNA: from in vitro characterization to in vivo function. *Nucleic Acids Research*, **2021**, 49, 3634-3650	20.1	18
31	PASTA: PARP activity screening and inhibitor testing assay. *STAR Protocols*, **2021**, 2, 100344	1.4	3
30	Chemical Proteomics Approach for Profiling the NAD Interactome. *Journal of the American Chemical Society*, **2021**, 143, 6787-6791	16.4	4

29	A molecular toolbox for ADP-ribosyl binding proteins.		1
28	Evaluation of 3- and 4-Phenoxybenzamides as Selective Inhibitors of the Mono-ADP-Ribosyltransferase PARP10. *ChemistryOpen*, **2021**, 10, 939-948	2.3	2
27	ADP-ribosyltransferase PARP11 suppresses Zika virus in synergy with PARP12. *Cell and Bioscience*, **2021**, 11, 116	9.8	4
26	Structure, Maintenance, and Regulation of Nuclear Pore Complexes: The Gatekeepers of the Eukaryotic Genome. *Cold Spring Harbor Perspectives in Biology*, **2021**,	10.2	3
25	Chemical genetic methodologies for identifying protein substrates of PARPs. *Trends in Biochemical Sciences*, **2021**,	10.3	3
24	Analogs of TIQ-A as inhibitors of human mono-ADP-ribosylating PARPs.		
23	A potent and selective PARP14 inhibitor decreases protumor macrophage gene expression and elicits inflammatory responses in tumor explants. *Cell Chemical Biology*, **2021**, 28, 1158-1168.e13	8.2	11
22	ADP-ribosyltransferases, an update on function and nomenclature. *FEBS Journal*, **2021**,	5.7	30
21	ADP-ribosylation: from molecular mechanisms to human disease. *Genetics and Molecular Biology*, **2019**, 43, e20190075	2	13
20	family-wide profiling and 3D modelling of the poly(ADP-ribose) polymerase superfamily. *Future Medicinal Chemistry*, **2020**, 12, 2105-2122	4.1	1
19	Rational design of selective inhibitors of PARP4. *RSC Medicinal Chemistry*, **2021**, 12, 1950-1957	3.5	2
18	ADP-Ribosylation as Post-Translational Modification of Proteins: Use of Inhibitors in Cancer Control. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	2
17	A molecular toolbox for ADP-ribosyl binding proteins. *Cell Reports Methods*, **2021**, 1, 100121		8
16	Assay technologies facilitating drug discovery for ADP-ribosyl writers, readers and erasers. *BioEssays*, **2021**, 44, e2100240	4.1	2
15	Analogs of TIQ-A as inhibitors of human mono-ADP-ribosylating PARPs. *Bioorganic and Medicinal Chemistry*, **2021**, 52, 116511	3.4	2
14	Beyond PARP1: The Potential of Other Members of the Poly (ADP-Ribose) Polymerase Family in DNA Repair and Cancer Therapeutics.. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 801200	5.7	5
13	ADP-Ribosylation Post-Translational Modification: An Overview with a Focus on RNA Biology and New Pharmacological Perspectives.. *Biomolecules*, **2022**, 12,	5.9	2
12	Potent 2,3-dihydrophthalazine-1,4-dione derivatives as dual inhibitors for mono-ADP-ribosyltransferases PARP10 and PARP15.. *European Journal of Medicinal Chemistry*, **2022**, 237, 114362	6.8	2

11	Research Progress on Mono-ADP-Ribosyltransferases in Human Cell Biology. *Frontiers in Cell and Developmental Biology*, **2022**, 10,	5.7	0
10	Synthesis, molecular docking, and cytotoxicity of quinazolinone and dihydroquinazolinone derivatives as cytotoxic agents.. *BMC Chemistry*, **2022**, 16, 35	3.7	
9	Methods for profiling the target and off-target landscape of PARP inhibitors. *Current Research in Chemical Biology*, **2022**, 2, 100027		
8	Medicinal Chemistry Perspective on Targeting Mono-ADP-Ribosylating PARPs with Small Molecules. *Journal of Medicinal Chemistry*,	8.3	3
7	Targeting PARP11 to avert immunosuppression and improve CAR T therapy in solid tumors. *Nature Cancer*,	15.4	3
6	Selective PARP1 Inhibitors, PARP1-based Dual-Target Inhibitors, PROTAC PARP1 Degraders, and Prodrugs of PARP1 Inhibitors for Cancer Therapy. **2022**, 106529		1
5	PARP10 Mediates Mono-ADP-Ribosylation of Aurora-A Regulating G2/M Transition of the Cell Cycle. **2022**, 14, 5210		1
4	Structure-guided design and characterization of a clickable, covalent PARP16 inhibitor. **2022**, 13, 13898-13906		0
3	Allosteric regulation of DNA binding and target residence time drive the cytotoxicity of phthalazinone-based PARP-1 inhibitors. **2022**, 29, 1694-1708.e10		1
2	Structurally distinct PARP7 inhibitors provide new insights into the function of PARP7 in regulating nucleic acid-sensing and IFN-β signaling. **2022**,		1
1	[1,2,4]Triazolo[3,4-b]benzothiazole Scaffold as Versatile Nicotinamide Mimic Allowing Nanomolar Inhibition of Different PARP Enzymes.		0